These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 27272172)

  • 1. Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy.
    Kobayashi K; Matsuyama H; Shimizu K; Fujii N; Inoue R; Yamamoto Y; Matsumoto H; Nagao K
    Jpn J Clin Oncol; 2016 Aug; 46(8):775-80. PubMed ID: 27272172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group.
    Kitamura H; Taguchi K; Kunishima Y; Yanase M; Takahashi A; Shigyo M; Tanaka T; Mutoh M; Fukuta F; Masumori N; Tsukamoto T
    Cancer Sci; 2011 Jun; 102(6):1171-5. PubMed ID: 21323791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy.
    Shinohara N; Harabayashi T; Suzuki S; Nagao K; Seki H; Murakumo M; Mitsuhashi K; Demura T; Nagamori S; Matsuyama H; Naito K; Nonomura K
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):402-7. PubMed ID: 16416335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors.
    Nakamura T; Ueda T; Oishi M; Nakanishi H; Fujihara A; Naya Y; Hongo F; Kamoi K; Okihara K; Miki T
    Int J Urol; 2015 Mar; 22(3):288-93. PubMed ID: 25393104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.
    Bajorin DF; McCaffrey JA; Dodd PM; Hilton S; Mazumdar M; Kelly WK; Herr H; Scher HI; Icasiano E; Higgins G
    Cancer; 2000 Apr; 88(7):1671-8. PubMed ID: 10738226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial.
    Bajorin DF; McCaffrey JA; Hilton S; Mazumdar M; Kelly WK; Scher HI; Spicer J; Herr H; Higgins G
    J Clin Oncol; 1998 Aug; 16(8):2722-7. PubMed ID: 9704723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors.
    Nonomura N; Oka D; Nishimura K; Nakayama M; Inoue H; Mizutani Y; Miki T; Okuyama A
    Int J Urol; 2007 Jun; 14(6):527-31. PubMed ID: 17593098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Less nephrotoxicity of paclitaxel and ifosfamide plus nedaplatin for refractory or relapsed germ cell tumors in patients with impaired renal function.
    Shiraishi T; Nakamura T; Takamura T; Oishi M; Yamada T; Yamada Y; Ueda T; Fujihara A; Hongo F; Okihara K; Ukimura O
    Int J Urol; 2020 Feb; 27(2):134-139. PubMed ID: 31701563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma.
    Kakutani S; Fukuhara H; Taguchi S; Nagata M; Niimi A; Hattori M; Miyazaki H; Fujimura T; Nakagawa T; Kume H; Igawa Y; Homma Y
    Jpn J Clin Oncol; 2015 Mar; 45(3):281-5. PubMed ID: 25425701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Paclitaxel, ifosfamide, nedaplatin (TIN) for patients with metastatic urothelial cancer].
    Suzuki S; Shinohara N; Harabayashi T; Seki H; Murakumo M; Ishikawa R; Demura T; Mitsuhashi K; Toyota H; Koyanagi T
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):561-5. PubMed ID: 15114700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.
    Galsky MD; Iasonos A; Mironov S; Scattergood J; Donat SM; Bochner BH; Herr HW; Russo P; Boyle MG; Bajorin DF
    Urology; 2007 Feb; 69(2):255-9. PubMed ID: 17320659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study.
    Krege S; Rembrink V; Börgermann C; Otto T; Rübben H
    J Urol; 2001 Jan; 165(1):67-71. PubMed ID: 11125366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy.
    Peng PJ; Ou XQ; Chen ZB; Liao H; Peng YL; Wang SY; Zhang HY; Lin Z
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):323-8. PubMed ID: 23728706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Salvage chemotherapy with paclitaxel, ifosphamide and nedaplatin for relapsed or refractory germ cell cancer].
    Nomoto T; Mizutani Y; Mikami K; Nakamura T; Nakanishi H; Kawauchi A; Miki T
    Nihon Hinyokika Gakkai Zasshi; 2006 May; 97(4):630-5. PubMed ID: 16768143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
    Milowsky MI; Nanus DM; Maluf FC; Mironov S; Shi W; Iasonos A; Riches J; Regazzi A; Bajorin DF
    J Clin Oncol; 2009 Sep; 27(25):4062-7. PubMed ID: 19636012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage chemotherapy with docetaxel, ifosfamide and nedaplatin (DIN) for patients with advanced germ cell tumors: a preliminary report.
    Yamada S; Saito H; Ohara S; Yamashita S; Mitsuzuka K; Namiki S; Miyazato M; Kaiho Y; Ito A; Nakagawa H; Ishidoya S; Arai Y
    Jpn J Clin Oncol; 2013 Jul; 43(7):734-9. PubMed ID: 23619987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma.
    Scandurra G; Scibilia G; Banna GL; D'Agate G; Lipari H; Gieri S; Scollo P
    J Gynecol Oncol; 2015 Apr; 26(2):118-24. PubMed ID: 25686397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of a phase II study.
    Zhang MQ; Liu SP; Wang XE
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):821-7. PubMed ID: 20207507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab.
    Khawandanah M; Baxley A; Pant S
    J Oncol Pharm Pract; 2015 Jun; 21(3):232-7. PubMed ID: 24627343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.